Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...
Im Neuenheimer Feld 582
Founded in 2000
Affimed Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Mar 25 15
Affimed reported unaudited Consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net loss was EUR 5.3 million, or EUR 0.22 per common share, compared to a net loss of EUR 2.6 million, or EUR 0.17 per common share for fourth quarter of 2013. The company reported revenue of EUR 81,000 compared to EUR4.6 million for fourth quarter of 2013 due to milestone achievement-related revenue recognition under the Amphivena collaboration in the 2013 period. Loss before tax was EUR 5,428,000 against EUR 2,542,000 a year ago. Net cash used in operating activities was EUR 5,444,000 against EUR 2,268,000 a year ago. Purchase of intangible assets was EUR 10,000 against EUR 5,000 a year ago. Purchase of leasehold improvements and equipment was EUR 18,000 against EUR 11,000 a year ago.
Net loss for the full year 2014 was EUR 0.3 million or EUR 0.01 per common share, compared to a loss of EUR 26.1 million or EUR 1.76 per common share for the full year 2013. The decrease is primarily related to a credit to the share-based payment expense resulting from a re-measurement gain at consummation of the IPO. Loss before tax was EUR 425,000 against EUR 26,100,000 a year ago. Net cash used in operating activities was EUR 10,547,000 against EUR 5,678,000 a year ago. Purchase of intangible assets was EUR 45,000 against EUR 23,000 a year ago. Purchase of leasehold improvements and equipment was EUR 260,000 against EUR 139,000 a year ago. Revenue was EUR 3,382,000 against EUR 5,087,000 a year ago. Operating loss was EUR 8,178,000 against EUR 15,703,000 a year ago. The increase in net cash used in operating activities was primarily related to the increase in cash based expenses for research and development (R&D) in connection with development and collaboration programs and general and administrative expenses in relation to the preparation for the IPO and other financing transactions.
Affimed N.V. Presents at BioCapital Europe 2015, Mar-26-2015 02:40 PM
Mar 23 15
Affimed N.V. Presents at BioCapital Europe 2015, Mar-26-2015 02:40 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.
Affimed N.V. to Report Q4, 2014 Results on Mar 25, 2015
Mar 18 15
Affimed N.V. announced that they will report Q4, 2014 results on Mar 25, 2015